Shire gets an FDA nod for extended-release ADHD drug; An inside look at veteran drug-delivery investor Terry McGuire;

> Laval, Quebec-based Labopharm, a developer of controlled-release drugs, reported a larger loss for the fourth quarter because it nearly doubled certain expenses. Story

> There was a worthy profile story about venture capitalist Terry McGuire of Polaris Venture Partners, a veteran investor in notable drug-delivery startups such as Advanced Inhalation Research (acquired by Alkermes ($ALKS)) and MicroCHIPS. Story

> Ireland-based specialty drug maker Shire ($SHPGY) said it garnered FDA approval of an extended-release formulation of the drug guanfacine for treating attention deficit and hyperactivity disorder. Shire release

> Enlyton, of Columbus, OH, licensed a tumor-seeking monoclonal antibody from ViroMed for enhancing cancer detection and drug delivery. Story

> Read some insights from scientists at the University of Copenhagen and elsewhere about how the surface features of nanoparticles used in drug delivery impact immune responses. Story

> Chinese medical devices maker Mindray Medical International Limited ($MR) has agreed to buy a controlling stake in Shenzhen Shenke Medical Instrument Technical Development Company, one of China's leading producers of infusion pumps. Financial details weren't disclosed. Mindray release

> Vancouver-based QLT Inc. ($QLTI), a developer of plugs inserted at the opening of the tear ducts to deliver eye treatments, reported that its fourth-quarter revenue was down 7.3 percent to $10 million and provided an update on its pipeline. QLT release